Cargando…

Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials

INTRODUCTION: In three phase III randomized controlled trials, ceftaroline fosamil was shown to be non-inferior to vancomycin plus aztreonam for the treatment of complicated skin and soft tissue infections (cSSTIs). This exploratory analysis evaluated the impact of underlying comorbidities on clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilcox, Mark, Yan, Jean Li, Gonzalez, Pedro L., Dryden, Matthew, Stone, Gregory G., Kantecki, Michal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847533/ https://www.ncbi.nlm.nih.gov/pubmed/34741280 http://dx.doi.org/10.1007/s40121-021-00557-w

Ejemplares similares

Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Correction to: Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections
por: Das, Shampa, et al.
Publicado: (2019)

Baseline Characteristics and Outcomes Among Patients with Complicated Skin and Soft Tissue Infections Admitted to the Intensive Care Unit: Analysis of the Phase 3 COVERS Randomized Trial of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam
por: Sánchez-García, Miguel, et al.
Publicado: (2020)

Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System
por: Torres, Antoni, et al.
Publicado: (2022)

Ceftaroline Fosamil: A Brief Clinical Review
por: Shirley, Debbie-Ann T., et al.
Publicado: (2013)

A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities
por: Dryden, Matthew, et al.
Publicado: (2016)

Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience
por: Johnson, Leonard B., et al.
Publicado: (2019)

Ceftaroline-fosamil: Acute eosinophilic pneumonia: case report
Publicado: (2021)

Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
por: Torres, Antoní, et al.
Publicado: (2023)

Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience
por: Santos, Paul D, et al.
Publicado: (2013)

The use of extrapolation based on modeling and simulation to support high‐dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft‐tissue infections
por: Chan, Phylinda L.S., et al.
Publicado: (2021)

Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE
por: Carreno, Joseph J., et al.
Publicado: (2014)

Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application
por: Yim, Juwon, et al.
Publicado: (2016)

A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators
por: Cristinacce, Andrew, et al.
Publicado: (2019)

Ceftaroline fosamil: A novel anti-Methicillin-resistant Staphylococcus aureus cephalosporin
por: Girish, C., et al.
Publicado: (2011)

Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit
por: Maggiore, Christy, et al.
Publicado: (2015)

809 Contemporary Experience with Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia
por: Johnson, Leonard B, et al.
Publicado: (2014)

679 Ceftaroline Fosamil (CPT-F) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients
por: Kaye, Keith, et al.
Publicado: (2014)

Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis
por: Sotgiu, Giovanni, et al.
Publicado: (2018)

Ceftaroline fosamil: clinical experience after 23-month prescription in a tertiary hospital
por: Álvarez, Alicia Alonso, et al.
Publicado: (2021)

Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia
por: Vazquez, Jose A., et al.
Publicado: (2015)

Ceftaroline Fosamil as an Alternative for a Severe Methicillin-resistant Staphylococcus aureus Infection: A Case Report
por: Jilani, Talha N, et al.
Publicado: (2018)

Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial
por: Zhuo, Chao, et al.
Publicado: (2022)

Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury
por: Faris, Janie, et al.
Publicado: (2015)

Ceftaroline in complicated skin and skin-structure infections
por: Hernandez, Paul O, et al.
Publicado: (2012)

Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia
por: Mpenge, Mbiye A, et al.
Publicado: (2015)

Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5‐Minute Infusion
por: Riccobene, Todd A., et al.
Publicado: (2021)

1567. Pharmacokinetic/Pharmacodynamic Target Attainment in Adult and Pediatric Patients following Administration of Ceftaroline Fosamil as a 5-Minute Infusion
por: Riccobene, Todd, et al.
Publicado: (2019)

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus
por: Claeys, Kimberly C., et al.
Publicado: (2019)

Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h
por: Cheng, Karen, et al.
Publicado: (2019)

678 Ceftaroline vs Vancomycin in Treatment for Skin and Soft Tissue Infections (SSTI) in Obese Patients
por: Nguyen, Hao, et al.
Publicado: (2014)

Ceftaroline Efficacy and Safety in Treatment of Complicated Skin and Soft Tissue Infection: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
por: Lan, Shao-Huan, et al.
Publicado: (2019)

Ceftaroline
por: Soriano, Alex
Publicado: (2021)

Update on the epidemiology of healthcare-acquired bacterial infections: focus on complicated skin and skin structure infections
por: Wilcox, Mark H, et al.
Publicado: (2021)

1245. In Vitro Activities of Ceftaroline and Comparator Agents Against Bacterial Pathogens Collected from Patients with Skin and Skin Structure Infections: ATLAS Global Surveillance Program 2012-2019
por: Hackel, Meredith, et al.
Publicado: (2021)

Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin
por: Eckmann, Christian, et al.
Publicado: (2010)

2376. In Vitro Activities of Ceftaroline and Comparator Agents Against Bacterial Pathogens Collected From Patients With Skin and Skin Structure Infections in Latin America: AWARE Surveillance Program 2017
por: Hackel, Meredith, et al.
Publicado: (2018)

Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America – results of AWARE surveillance 2012
por: Hoban, Daryl, et al.
Publicado: (2015)

Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
por: Goodman, Julian J, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6a08pvsqojqtb97v5qbpq8squn